What is the effective date for WIPO published applications to be considered prior art under AIA?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-29 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. The effective date for WIPO published applications to be considered…

Read More

When did the new requirements for “specifically defined” nucleotides and amino acids come into effect?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-29 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. According to MPEP 2412.03(a), the new requirements for “specifically defined”…

Read More

What are linking claims in patent applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-27 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. Linking claims are special claims in patent applications that link…

Read More

What classification system is used for utility patents and applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-27 2 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. Utility patents, applications, and patent application publications are classified under…

Read More

What is the USPTO’s current policy on nucleotide sequences in patent applications?

Source: FAQ (MPEP-Based)BlueIron Update: 2024-09-27 10 Rules5 Related FAQs This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice. The USPTO’s current policy on nucleotide sequences in patent applications…

Read More